Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Stéphane Mouret
Based on 5 articles published since 2010
(Why 5 articles?)

Between 2010 and 2020, Stephane Mouret wrote the following 5 articles about Melanoma.
+ Citations + Abstracts
1 Review Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. 2017

Busser, Benoit / Lupo, Julien / Sancey, Lucie / Mouret, Stéphane / Faure, Patrice / Plumas, Joel / Chaperot, Laurence / Leccia, Marie Thérèse / Coll, Jean Luc / Hurbin, Amandine / Hainaut, Pierre / Charles, Julie. ·Biochemistry Pharmacology and Toxicology Department, Grenoble University Hospital, Grenoble, France. · Institute for Advanced Biosciences, UGA/INSERM U1209/CNRS UMR5309, Grenoble, France. · Virology Laboratory, Grenoble University Hospital, Grenoble, France. · Institut de Biologie Structurale, CEA-CNRS UMR 5075/UGA, Grenoble, France. · Dermatology Unit, Grenoble University Hospital, Grenoble, France. · UGA, Laboratory of Hypoxy Physiopathology Study, INSERM U1042, Grenoble, France. · EFS Rhone-Alpes-Auvergne, Grenoble, France. ·Biomed Res Int · Pubmed #28484715.

ABSTRACT: Melanoma is a cutaneous cancer with an increasing worldwide prevalence and high mortality due to unresectable or metastatic stages. Mutations in

2 Article T-cell receptor diversity as a prognostic biomarker in melanoma patients. 2020

Charles, Julie / Mouret, Stephane / Challende, Isabelle / Leccia, Marie-Therese / De Fraipont, Florence / Perez, Solene / Plantier, Nadia / Plumas, Joel / Manuel, Manuarii / Chaperot, Laurence / Aspord, Caroline. ·Immunobiology and Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France. · Dermatology Clinic, Grenoble University Hospital, Grenoble, France. · Department of Biochemistry of Cancers and Biotherapies, Grenoble University Hospital, Grenoble, France. · ImmunID, Grenoble, France. · R&D-Laboratory, Etablissement Français du Sang Auvergne Rhone-Alpes, Grenoble, France. ·Pigment Cell Melanoma Res · Pubmed #31971658.

ABSTRACT: There is increasing evidence that T-cell receptor (TCR) repertoire diversity can be a predictive biomarker of immune responses in cancer patients. However, the characteristics of the T-cell repertoire together with its prognostic significance in melanoma patients and impact on disease progression remain unknown. We investigated the combinatorial TCR repertoire diversity by semi-quantitative multi-N-plex PCR in peripheral blood samples from 44 melanoma patients together with seven matched metastatic lymph nodes and explored its potential predictive value on clinical prognosis. The diversity was quantified by calculating both richness (number of different specificities) and evenness (relative abundance of the different specificities). Our results revealed that a higher TCR repertoire diversity in blood of patients was associated with a longer PFS, while divpenia (low repertoire diversity) was linked with poor prognosis. The diversity was significantly higher in patients undergoing late relapse and long survival compared to patients who progressed rapidly. Interestingly, the TCR repertoire diversity in tumor may have a potential prognostic value. Thus, our study highlights that the TCR repertoire diversity is a prognostic indicator of clinical outcome in patients with melanoma.

3 Article The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome. 2019

Girard, Pauline / Charles, Julie / Cluzel, Camille / Degeorges, Emmanuelle / Manches, Olivier / Plumas, Joel / De Fraipont, Florence / Leccia, Marie-Therese / Mouret, Stephane / Chaperot, Laurence / Aspord, Caroline. ·Etablissement Français du Sang Auvergne Rhone-Alpes, R&D-Laboratory, Grenoble, France. · University Grenoble Alpes, EMR EFS-UGA-INSERM U1209- CNRS, Immunobiology & Immunotherapy of Chronic Diseases, Grenoble, France. · Dermatology clinic, Grenoble University Hospital, Grenoble, France. · pDCline Pharma, Grenoble, France. · Department of Biochemistry of Cancers and Biotherapies, Grenoble University Hospital, Grenoble, France. ·Oncoimmunology · Pubmed #31413911.

ABSTRACT: γδT cells hold a pivotal role in tumor immunosurveillance through their prompt activation and cytokine secretion, their ability to kill tumor cells in an Human Leukocyte Antigen (HLA)-unrestricted manner, and their combination of features of both innate and adaptive immunity. These unique properties and functional plasticity render them very attractive both as targets and vectors for cancer immunotherapy. Yet, these potent and fascinating antitumor effectors have not been extensively explored in melanoma. We provided here a detailed investigation of the phenotypic and functional properties of circulating and tumor-infiltrating γδT cells in melanoma patients, and their impact on clinical evolution. High proportions of circulating- and tumor-infiltrating γδT and δ2+ subset were associated with better clinical outcome. We reported however that circulating and tumor-infiltrating γδT cells from melanoma patients displayed an altered expression of NCR, KIR, and immune checkpoints, and identified NKp44, PD1, 41BB/41BBL, TIM3, and LAG3 as crucial checkpoints allowing immune escape and tumor progression. Notably, melanoma drastically impaired the ability of γδT cells to exhibit activation molecules, secrete cytokines, and display cytotoxicity toward melanoma in response to stimulation with phosphoantigens. It drove them toward regulatory and Th17 profiles associated with poor clinical outcomes. Our study highlights that melanoma hijacked γδT cells to escape from immune control, and revealed that circulating and tumor-infiltrating γδT cell features are promising potential biomarkers of clinical evolution. Such understanding of the physiopathology of γδT cells may help designing new therapeutic approaches exploiting the antitumor potential of γδT cells while counteracting their skewing by tumors to improve patient outcomes.

4 Article The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. 2018

Charles, Julie / Chaperot, Laurence / Revol, Bruno / Baudin, Marine / Mouret, Stephane / Hamon, Agnes / Leccia, Marie-Therese / Plumas, Joel / Aspord, Caroline. ·University Grenoble Alpes, Grenoble, France. · Immunobiology& Immunotherapy of Chronic Diseases, U1209, INSERM, La Tronche, France. · Dermatology, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, France. · R&D Laboratory, Etablissement Français du Sang Rhone-Alpes, La Tronche, France. · Pharmacovigilance Department, CHU Grenoble Alpes, Grenoble, France. · Laboratoire Jean Kuntzmann, Universite Grenoble Alpes, Grenoble, France. ·Pigment Cell Melanoma Res · Pubmed #28741900.

ABSTRACT: The advent of immune checkpoint blockers and targeted therapies has changed the outcome of melanoma. However, many patients experience relapses, emphasizing the need for predictive and prognostic biomarkers. We developed a strategy based on plasmacytoid dendritic cells (pDCs) loaded with melanoma tumor antigens that allows eliciting highly efficient antitumor T-cell responses. We used it to investigate antitumor T-cell functionality in peripheral blood mononuclear cells and tumor-infiltrating lymphocytes from melanoma patients. The pDCs elicited tumor-specific T cells in different proportions and displaying diverse functional features, dependent upon the stage of the disease, but independent of the histological parameters at diagnosis. Strikingly, the avidity of the MelA-specific T cells triggered by the pDCs was found to predict patient relapse time and overall survival. Our findings highlighted unexplored aspects of antitumor T-cell responsiveness in melanoma, and revealed for the first time the structural avidity of tumor-specific T cells as a crucial feature for predicting clinical evolution.

5 Article Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. 2012

Noonan, Frances P / Zaidi, M Raza / Wolnicka-Glubisz, Agnieszka / Anver, Miriam R / Bahn, Jesse / Wielgus, Albert / Cadet, Jean / Douki, Thierry / Mouret, Stephane / Tucker, Margaret A / Popratiloff, Anastas / Merlino, Glenn / De Fabo, Edward C. ·Laboratory of Photobiology and Photoimmunology, Department of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia 20037, USA. ·Nat Commun · Pubmed #22673911.

ABSTRACT: Malignant melanoma of the skin (CMM) is associated with ultraviolet radiation exposure, but the mechanisms and even the wavelengths responsible are unclear. Here we use a mammalian model to investigate melanoma formed in response to precise spectrally defined ultraviolet wavelengths and biologically relevant doses. We show that melanoma induction by ultraviolet A (320-400 nm) requires the presence of melanin pigment and is associated with oxidative DNA damage within melanocytes. In contrast, ultraviolet B radiation (280-320 nm) initiates melanoma in a pigment-independent manner associated with direct ultraviolet B DNA damage. Thus, we identified two ultraviolet wavelength-dependent pathways for the induction of CMM and describe an unexpected and significant role for melanin within the melanocyte in melanomagenesis.